Stockscreener 앱 받기
26.48
0.98%
0.255
전일 마감가:
$26.22
열려 있는:
$26.26
하루 거래량:
1.89M
Relative Volume:
0.87
시가총액:
$11.81B
수익:
$2.24B
순이익/손실:
$673.24M
주가수익비율:
235.33
EPS:
0.1125
순현금흐름:
$2.67B
1주 성능:
+3.51%
1개월 성능:
-4.59%
6개월 성능:
-2.55%
1년 성능:
-1.94%
1일 변동 폭
$26.23
$26.66
1주일 범위
$25.10
$26.66
52주 변동 폭
$25.10
$31.66
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| RPRX | 26.48 | 11.81B | 2.24B | 673.24M | 2.67B | 0.1125 |
| VRTX | 450.42 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.72 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.27 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.44 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.08 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma (NASDAQ:RPRX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Victory Capital Management Inc. Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Amalgamated Bank Sells 48,057 Shares of Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
Royalty Pharma stock hits 52-week low at $25.2 amid market shifts - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Sets New 52-Week LowTime to Sell? - MarketBeat
Simplify Asset Management Inc. Increases Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
(RPRX) Technical Data - Stock Traders Daily
Royalty Pharma Announces Inaugural Prize for Impact in Healthcare - The Manila Times
Royalty Pharma Awards Inaugural Healthcare Prize to Michael Milken for Cancer Research Impact | RPRX Stock News - StockTitan
3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade - The Motley Fool
Ex-Dividend Reminder: Cencora, Royalty Pharma and Brookline Bancorp - Nasdaq
Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX) - Simply Wall St
Royalty Pharma's (NASDAQ:RPRX) Profits May Not Reveal Underlying Issues - Yahoo Finance
Syndax shares slide despite pivotal trial success - The Pharma Letter
New South Capital Management Inc. Has $69.77 Million Stake in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Baillie Gifford & Co. - MarketBeat
Los Angeles Capital Management LLC Lowers Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Van ECK Associates Corp Boosts Stock Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma Q3 2024 Earnings Preview - MSN
Summit Global Investments Purchases New Position in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Executive Wealth Management LLC - MarketBeat
Royalty Pharma Stock: Massive Opportunity Ahead (NASDAQ:RPRX) - Seeking Alpha
Morgan Stanley's Strategic Reduction in Royalty Pharma PLC Holdi - GuruFocus.com
Royalty Pharma plc (NASDAQ:RPRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Royalty Pharma to Acquire Royalty Interest in Geron's RYTELO for $125 Million - The Manila Times
Royalty Pharma plc (RPRX) to Acquire Royalty Interest in Geron’s (GERN) RYTELO for $125M - StreetInsider.com
Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million - StockTitan
Royalty Pharma plc (NASDAQ:RPRX) Shares Acquired by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma PLC (RPRX) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic Acquisitions - Investing.com Canada
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - Yahoo Finance
Royalty Pharma Reports Strong Q3 2024 Results - TipRanks
Compared to Estimates, Royalty Pharma (RPRX) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - Investing.com Nigeria
Royalty Pharma reports robust Q3 growth, raises guidance By Investing.com - ழ தொலைக்காட்சி
Earnings call: Royalty Pharma reports robust Q3 growth, raises guidance - Investing.com
Royalty Pharma Reports Third Quarter 2024 Results - ForexTV.com
Royalty Pharma plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Royalty Pharma Q3 Soars: 15% Revenue Growth, $1.2B Deployment Drives Guidance Boost | RPRX Stock News - StockTitan
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
River Road Asset Management LLC Has $13.30 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX) - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Insights Ahead: Royalty Pharma's Quarterly Earnings - Benzinga
Royalty Pharma (NASDAQ:RPRX) Raised to “Buy” at StockNews.com - Defense World
Syndax agrees funding with Royalty Pharma for Niktimvo US sales - Yahoo Finance
Royalty Pharma plc and Syndax Pharmaceuticals Enter into $350 Million Royalty Funding Agreement for Niktimvo - Marketscreener.com
Royalty Pharma (NASDAQ:RPRX) Upgraded at StockNews.com - MarketBeat
Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo - The Manila Times
Syndax secures $350 million in royalty funding from Royalty Pharma By Investing.com - Investing.com UK
Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™ - StockTitan
With 72% ownership, Royalty Pharma plc (NASDAQ:RPRX) boasts of strong institutional backing - Simply Wall St
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
로열티 파마 주식 (RPRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RIGGS RORY B | Director |
Jan 03 '24 |
Sale |
27.79 |
199,098 |
5,532,276 |
55,801 |
| RIGGS RORY B | Director |
Jan 04 '24 |
Sale |
27.55 |
35,702 |
983,504 |
20,099 |
| Avara Management Ltd | 10% Owner |
Dec 29 '23 |
Sale |
28.04 |
65,803 |
1,845,406 |
2,477,520 |
| Avara Management Ltd | 10% Owner |
Dec 28 '23 |
Sale |
28.20 |
209,863 |
5,918,934 |
2,543,323 |
| Avara Management Ltd | 10% Owner |
Dec 27 '23 |
Sale |
28.01 |
41,729 |
1,168,754 |
2,753,186 |
| Avara Management Ltd | 10% Owner |
Dec 15 '23 |
Sale |
28.01 |
10,229 |
286,499 |
2,794,915 |
| Avara Management Ltd | 10% Owner |
Dec 14 '23 |
Sale |
28.91 |
364,441 |
10,534,276 |
2,805,144 |
| Avara Management Ltd | 10% Owner |
Dec 13 '23 |
Sale |
28.95 |
307,935 |
8,916,012 |
3,169,585 |
1.80%
0.42%
자본화:
|
볼륨(24시간):